BioCardia, Inc. (BCDA)
BCDA Stock Price Chart
Explore BioCardia, Inc. interactive price chart. Choose custom timeframes to analyze BCDA price movements and trends.
BCDA Company Profile
Discover essential business fundamentals and corporate details for BioCardia, Inc. (BCDA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Nov 1996
Employees
17.00
Website
https://www.biocardia.comCEO
Peter A. Altman
Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
BCDA Financial Timeline
Browse a chronological timeline of BioCardia, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 11 Nov 2025
Earnings released on 11 Aug 2025
EPS came in at -$0.40 surpassing the estimated -$0.50 by +20.00%.
Earnings released on 14 May 2025
EPS came in at -$0.59 falling short of the estimated -$0.39 by -51.28%.
Earnings released on 26 Mar 2025
EPS came in at -$0.25 surpassing the estimated -$0.87 by +71.26%, while revenue for the quarter reached $25.00K , beating expectations by +11.11%.
Earnings released on 13 Nov 2024
EPS came in at -$0.61 surpassing the estimated -$1.19 by +48.74%, while revenue for the quarter reached $58.00K , beating expectations by +190.00%.
Earnings released on 13 Aug 2024
EPS came in at -$0.88 falling short of the estimated -$0.10 by -780.00%, while revenue for the quarter reached $3.00K , missing expectations by -94.00%.
Stock split effective on 30 May 2024
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2024
EPS came in at -$1.35 surpassing the estimated -$3.00 by +55.00%, while revenue for the quarter reached $55.00K .
Earnings released on 27 Mar 2024
EPS came in at -$1.35 surpassing the estimated -$1.65 by +18.18%, while revenue for the quarter reached $13.00K , missing expectations by -85.56%.
Earnings released on 8 Nov 2023
EPS came in at -$1.80 matching the estimated -$1.80, while revenue for the quarter reached $357.00K , beating expectations by +296.67%.
Earnings released on 9 Aug 2023
EPS came in at -$2.55 falling short of the estimated -$2.25 by -13.33%, while revenue for the quarter reached $43.00K , missing expectations by -64.17%.
Earnings released on 10 May 2023
EPS came in at -$2.55 falling short of the estimated -$1.95 by -30.77%, while revenue for the quarter reached $64.00K , missing expectations by -81.18%.
Earnings released on 29 Mar 2023
EPS came in at -$2.40 surpassing the estimated -$2.70 by +11.11%, while revenue for the quarter reached $106.00K , beating expectations by +6.00%.
Earnings released on 9 Nov 2022
EPS came in at -$2.55 surpassing the estimated -$3.45 by +26.09%, while revenue for the quarter reached $212.00K , beating expectations by +87.61%.
Earnings released on 10 Aug 2022
EPS came in at -$2.10 surpassing the estimated -$4.20 by +50.00%, while revenue for the quarter reached $974.00K , beating expectations by +958.70%.
Earnings released on 11 May 2022
EPS came in at -$2.85 falling short of the estimated -$2.25 by -26.67%, while revenue for the quarter reached $60.00K , missing expectations by -68.42%.
Earnings released on 29 Mar 2022
EPS came in at -$3.15 matching the estimated -$3.15, while revenue for the quarter reached $79.00K , beating expectations by +141.22%.
Earnings released on 10 Nov 2021
EPS came in at -$2.40 falling short of the estimated -$0.21 by -1.04K%, while revenue for the quarter reached $821.00K .
Earnings released on 12 Aug 2021
EPS came in at -$3.00 surpassing the estimated -$3.15 by +4.76%, while revenue for the quarter reached $69.00K , meeting expectations.
Earnings released on 13 May 2021
EPS came in at -$2.70 surpassing the estimated -$3.15 by +14.29%, while revenue for the quarter reached $46.00K , missing expectations by -20.00%.
Earnings released on 30 Mar 2021
EPS came in at -$2.40 surpassing the estimated -$4.65 by +48.39%, while revenue for the quarter reached $46.00K .
Earnings released on 10 Nov 2020
EPS came in at -$4.50 falling short of the estimated -$4.20 by -7.14%, while revenue for the quarter reached $34.00K , beating expectations by +7.69%.
BCDA Stock Performance
Access detailed BCDA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.